Alnylam Pharmaceuticals, Inc. (ALNY) income statement
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$147.82−1.58 (-1.06%)
Close on Nov 19, 2026Market cap $19.80BP/E 7.7Yield –
Alnylam Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 77.4%
- Operating margin
- 19.5%
- Net margin
- 52.8%
- Return on equity, FY2025
- 73.3%
Financial strength
- Current ratio
- 2.48
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 85.0%
Valuation
- P/E ratio
- 7.7
- Price to sales
- 3.95
- Price to book
- 5.49
- Dividend yield
- –
See a number that looks wrong?